Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.news

KFSH&RC-Madinah Receives Prestigious 2023 Press Ganey Human Experience Guardian…

RIYADH, Saudi Arabia, Jan.29, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH&RC) in Madinah has won the 2023 Human Experience Guardian of Excellence Award by Press Ganey for its exceptional performance in outpatient services throughout the past year. This prestigious recognition honored a distinguished group of healthcare institutions, from approximately 1500 facilities globally, for being amongst the top 5% performers in patient experience in...

The combination of Novozymes and Chr. Hansen is now successfully completed…

Today, the proposed combination of the legacy companies Novozymes and Chr. Hansen is successfully completed, establishing the company Novonesis. Novonesis is a world-leading biosolutions partner for better business, healthier lives, and a healthier planet. The combined company brings together 10,000 people worldwide and an expertise that spans more than 30 different industries. Novonesis is already assisting companies around the world in meeting both business needs and the needs of the planet...

Completion of the combination between Novozymes and Chr. Hansen

January 29, 2024 – Company announcement no. 2 Please see attachment. CONTACT INFORMATION Investor Relations Tobias Cornelius Bjorklund+45 3077 8682tobb@novozymes.com Anders Enevoldsen+45 5350 1453adev@novozymes.comPress Relations Lina Danstrup+45 3077 0552lind@novozymes.com Attachment No. 2 Completion of the combination between Novozymes and Chr. Hansen

Completion of the combination between Novozymes and Chr. Hansen

Please read the full announcement in PDF Attachment 2024_02_Completion_Of_The_Combination

Esaote unveils two new Ultrasound Systems at Arab Health: MyLab™A50 and…

MyLab™A50 and MyLab™A70 embody the concept of Agility and are engineered to perform seamlessly in diverse clinical settings. With compact footprint, battery-operated lightweight and mobile design they meet the demands of most healthcare professionals. MyLab™A50 and MyLab™A70embody the concept of Agility and are engineered to perform seamlessly in diverse clinical settings. With compact footprint, battery-operated lightweight and mobile design they meet the demands of most healthcare...

Orion Corporation and Newel Health enter into licensing agreement for a digital…

ORION CORPORATIONPRESS RELEASE29 JANUARY 2024 at 11.00 EET Orion Corporation and Newel Health enter into licensing agreement for a digital therapeutic (DTx) ODD-403 (“Rohkea”) in pain Orion Corporation (“Orion”) and Newel Health (“Newel”) have entered into a license agreement regarding ODD-403 (“Rohkea”), a digital therapeutic (DTx) developed by Orion for patients suffering from chronic pain and particularly from fear of movement and re-injury. Under the terms of the...

Daewoong Pharmaceutical's Bersiporocin Receives 'Orphan Drug Designation' in…

IPF is characterized by abnormal collagen accumulation in the lungs, reducing lung function. With a global incidence rate of about 13 cases per 100,000 people and a 5-year survival rate of only 40%, there's a pressing need for more effective and safer treatments. IPF is characterized by abnormal collagen accumulation in the lungs, reducing lung function. With a global incidence rate of about 13 cases per 100,000 people and a 5-year survival rate of only 40%, there's a pressing need for more...

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for…

The study, which assessed the pharmacokinetics, safety, and tolerability of AVT03 compared to Prolia® in healthy adult subjects, met its primary endpointsProlia® and Xgeva® (denosumab) are indicated for the treatment of bone diseaseAlvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive top-line results from a pharmacokinetic (PK) study for AVT03, a biosimilar candidate...

Sequana Medical announces FDA acceptance for substantive review of the Premarket…

PRESS RELEASE Acceptance and filing review is a first step in the PMA review processIndicates PMA application is sufficiently complete for in-depth reviewReceived in advance of anticipated timing Ghent, Belgium – 29 January 2024– Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that the Premarket Approval (PMA) application for...

ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the…

ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal ®ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies Phase 1b open label trial confirms safety and tolerability of 120 mg and 200 mg dosing of ARM210 daily in patients with Ryanodine Receptor 1 Related MyopathiesProvides first signs of clinical efficacy improving fatigue and proximal muscle strength in patients at 200 mg dailyCorroborates allosteric mechanism of action of Rycal ®ARM210 to restore...

Non-Postoperative Acute Pain Treatment Market to Exhibit Enormous Growth During…

Key Takeaways from the Non-Postoperative Acute Pain Market Report Key Takeaways from the Non-Postoperative Acute Pain Market Report Discover which therapies are expected to grab the major non-postoperative acute pain market share @Non-Postoperative Acute Pain Market Report Non-Postoperative Acute Pain Overview Non-postoperative acute pain pertains to immediate discomfort stemming from various origins unrelated to surgical interventions. It can arise from diverse factors such...

Colposcopy Devices Global Market Likely to Exhibit Substantial Growth at a CAGR…

Key Takeaways from the Colposcopy Devices Market Report Key Takeaways from the Colposcopy Devices Market Report To read more about the latest highlights related to the colposcopy devices market, get a snapshot of the key highlights entailed in theGlobal Colposcopy Devices Market Report Colposcopy Devices Overview Colposcopy devices play a crucial role in the field of gynecology and women's health by providing a detailed and magnified examination of the cervix, vagina, and vulva...

ACCLARO MEDICAL TO SHOWCASE INNOVATIVE LASER-CORING APPLICATION OF ITS…

Leading laser authority David J. Goldberg, MD, a board-certified dermatologist, and director of cosmetic dermatology at Schweiger Dermatology Group in New York City, will provide an in-depth review of Acclaro's UltraClear Laser, with a focus on the clinical genius of Laser-Coring, at IMCAS on Thursday, February 1st at 3:45. Leading laser authorityDavid J. Goldberg, MD,a board-certified dermatologist, and director of cosmetic dermatology at Schweiger Dermatology Group inNew York City,...

AB Science announces an update in the marketing authorization application of…

PRESS RELEASEAB SCIENCE ANNOUNCES AN UPDATE IN THE MARKETING AUTHORIZATION APPLICATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AT THE EUROPEAN MEDICINES AGENCYA DECISION FROM THE EUROPEAN MEDICINES AGENCY IS EXPECTED DURING THE SECOND QUARTER OF 2024Paris, 26 January, 2024, 6pm CETAB Science SA(Euronext – FR0010557264 – AB) announced that the Committee for Medicinal Products for Human Use (CHMP) has proposed that AB Science submit a written response to the List of...

Zealand Pharma major shareholder announcement: Van Herk Investments

Company announcement – No. 6 / 2024 Zealand Pharma major shareholder announcement: Van Herk InvestmentsCopenhagen, Denmark, 26 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 26 January 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:...

Regenerative Medicine Market Worth $49.0 Billion | MarketsandMarkets™.

Browse in-depth TOC on "Regenerative Medicine Market" Browse in-depth TOC on "Regenerative Medicine Market" 258 - Tables 48 - Figures 303 - Pages Regenerative Medicine Market Scope: Cell therapy segment accounted for the largest share of the regenerative medicine market Based on product, the regenerative medicine market is segmented into gene therapy, cell therapy (stem cell therapy [cell transplantations, stem cell therapy products {Autologous stem cell...

RoboUP Introduces the Genesis of Rhino 1 Robot Mower: Strength, Resilience, and…

Rhino 1's journey begins with our commitment to meeting user needs. Developed in response to valuable insights from our user community, Rhino 1 reflects a powerful blend of adaptability and superior mowing performance. The product's naming process commenced in March 2023 and unfolded over six months, encapsulating the spirit of Rhino in every feature. Rhino 1's journey begins with our commitment to meeting user needs. Developed in response to valuable insights from ouruser community, Rhino 1...

Ketones Market worth $765 million by 2028 - Exclusive Report by…

Browse in-depth TOC on "Ketones Market" Browse in-depth TOC on "Ketones Market" 110 – Tables 35 – Figures 160 – Pages Ketones Market Expansion Fueled by Health Awareness, Fitness Trends, Diverse Applications, and Industry Innovations. The ketones market is expanding rapidly, driven by a confluence of factors. Growing awareness of the health benefits associated with ketogenic diets and lifestyles has spurred increased consumer interest. This surge is further propelled by a...

All necessary regulatory approvals have been obtained for the combination of…

January 26, 2024 – Company announcement no. 1 Please see attachment.Contact informationInvestor RelationsDisa Tuominen +45 6038 5826dkditu@chr-hansen.comPress RelationsSanne Seyer-Hansen +45 6038 6207dksash@chr-hansen.comAttachment No. 1 All necessary regulatory approvals have been obtained

All necessary regulatory approvals have been obtained for the combination of…

Please read the full announcement in PDF Attachment 2024_01_All_Regulatory_Approvals_Obtained

Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024

ORION CORPORATIONPRESS RELEASE26 JANUARY 2024 at 09.00 EET Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024 Orion presented yesterday at the 2024 ASCO GU Cancers Symposium a poster with additional data from the ongoing Phase II CYPIDES trial evaluating the safety and efficacy of ODM-208 (or MK-5684), an investigational, oral CYP11A1 inhibitor, in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) with and...

KFSH&RC-Madinah Receives Prestigious 2023 Press Ganey Human Experience Guardian…

The combination of Novozymes and Chr. Hansen is now successfully completed…

Completion of the combination between Novozymes and Chr. Hansen

Completion of the combination between Novozymes and Chr. Hansen

Esaote unveils two new Ultrasound Systems at Arab Health: MyLab™A50 and…

Orion Corporation and Newel Health enter into licensing agreement for a digital…

Daewoong Pharmaceutical's Bersiporocin Receives 'Orphan Drug Designation' in…

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for…

Sequana Medical announces FDA acceptance for substantive review of the Premarket…

ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the…

Philips delivers strong full-year results; agrees with FDA on terms of consent…

Introducing Sechrist's Innovative eHEAL and 3300HM Hyperbaric Chamber

Estonia's Digital Health Triumph Shines at Arab Health 2024: E-health Sector…

Non-Postoperative Acute Pain Treatment Market to Exhibit Enormous Growth During…

Colposcopy Devices Global Market Likely to Exhibit Substantial Growth at a CAGR…

ACCLARO MEDICAL TO SHOWCASE INNOVATIVE LASER-CORING APPLICATION OF ITS…

AB Science announces an update in the marketing authorization application of…

Zealand Pharma major shareholder announcement: Van Herk Investments

Regenerative Medicine Market Worth $49.0 Billion | MarketsandMarkets™.

RoboUP Introduces the Genesis of Rhino 1 Robot Mower: Strength, Resilience, and…

Ketones Market worth $765 million by 2028 - Exclusive Report by…

All necessary regulatory approvals have been obtained for the combination of…

All necessary regulatory approvals have been obtained for the combination of…

Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024